Mapel, Douglas W.; Roberts, Melissa H. - In: PharmacoEconomics 30 (2012) 10, pp. 869-885
such as Markov modelling, and they have usually found that newer therapies have favourable cost effectiveness. However, new …, known as exacerbations, and approaches to modelling the cost benefit of exacerbation reduction; (iii) quality …; (v) the limitations of Markov modelling; and (vi) the problem of outliers. …